AR061792A1 - Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa - Google Patents
Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampaInfo
- Publication number
- AR061792A1 AR061792A1 ARP070102955A ARP070102955A AR061792A1 AR 061792 A1 AR061792 A1 AR 061792A1 AR P070102955 A ARP070102955 A AR P070102955A AR P070102955 A ARP070102955 A AR P070102955A AR 061792 A1 AR061792 A1 AR 061792A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered
- optionally comprises
- optionally substituted
- species selected
- Prior art date
Links
- 102000003678 AMPA Receptors Human genes 0.000 title abstract 2
- 108090000078 AMPA Receptors Proteins 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 230000000946 synaptic effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000002837 carbocyclic group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 230000009782 synaptic response Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06116592 | 2006-07-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061792A1 true AR061792A1 (es) | 2008-09-24 |
Family
ID=37226676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102955A AR061792A1 (es) | 2006-07-04 | 2007-07-02 | Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7820707B2 (enExample) |
| EP (1) | EP2041124B1 (enExample) |
| JP (1) | JP2009541404A (enExample) |
| KR (1) | KR20090027672A (enExample) |
| CN (1) | CN101484448B (enExample) |
| AR (1) | AR061792A1 (enExample) |
| AU (1) | AU2007271469B2 (enExample) |
| CA (1) | CA2655680A1 (enExample) |
| IL (1) | IL196302A0 (enExample) |
| MX (1) | MX2008016494A (enExample) |
| NZ (1) | NZ573325A (enExample) |
| PE (1) | PE20080378A1 (enExample) |
| TW (1) | TW200817385A (enExample) |
| WO (1) | WO2008003452A1 (enExample) |
| ZA (1) | ZA200810165B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2718727A1 (en) * | 2008-03-25 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| WO2011036885A1 (ja) * | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2011036889A1 (ja) * | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| CA2806436C (en) | 2010-08-10 | 2019-09-10 | Syngenta Participations Ag | Process for the preparation of 3-haloalkylpyrazoles |
| JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| AU2014304562B8 (en) | 2013-08-08 | 2018-07-05 | Galapagos Nv | Thieno[2,3-c]pyrans as CFTR modulators |
| CN103772282B (zh) * | 2014-02-26 | 2015-09-23 | 上海毕得医药科技有限公司 | 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法 |
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| CN107286114B (zh) * | 2016-04-13 | 2020-08-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Ampa受体增效剂的脑靶向前药及其医药用途 |
| GB201702221D0 (en) * | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU771358B2 (en) * | 1997-11-21 | 2004-03-18 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| CH1196397H1 (de) * | 1999-06-02 | 2007-05-31 | Nps Pharma Inc | Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems. |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| US20040171603A1 (en) | 2001-05-18 | 2004-09-02 | Janos Pato | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor |
| CN1255413C (zh) * | 2001-06-14 | 2006-05-10 | 阿克佐诺贝尔公司 | 作为ampa受体正性调节剂的(吡啶并/噻吩并)－[f]－氧杂吖庚因－5－酮衍生物 |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| WO2005040110A1 (en) | 2003-10-08 | 2005-05-06 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| WO2005070916A1 (en) | 2004-01-09 | 2005-08-04 | Eli Lilly And Company | Thiophene and furan compounds |
| EP1802634A2 (en) | 2004-10-20 | 2007-07-04 | Compass Pharmaceuticals LLC | Thiophens and their use as anti-tumor agents |
-
2007
- 2007-06-14 TW TW096121620A patent/TW200817385A/zh unknown
- 2007-06-29 US US11/771,198 patent/US7820707B2/en active Active
- 2007-07-02 JP JP2009517024A patent/JP2009541404A/ja not_active Ceased
- 2007-07-02 NZ NZ573325A patent/NZ573325A/en unknown
- 2007-07-02 EP EP07801415.6A patent/EP2041124B1/en active Active
- 2007-07-02 AR ARP070102955A patent/AR061792A1/es unknown
- 2007-07-02 CN CN2007800248081A patent/CN101484448B/zh not_active Expired - Fee Related
- 2007-07-02 CA CA002655680A patent/CA2655680A1/en not_active Abandoned
- 2007-07-02 KR KR1020087031534A patent/KR20090027672A/ko not_active Withdrawn
- 2007-07-02 AU AU2007271469A patent/AU2007271469B2/en not_active Ceased
- 2007-07-02 MX MX2008016494A patent/MX2008016494A/es active IP Right Grant
- 2007-07-02 WO PCT/EP2007/005851 patent/WO2008003452A1/en not_active Ceased
- 2007-07-03 PE PE2007000848A patent/PE20080378A1/es not_active Application Discontinuation
-
2008
- 2008-11-28 ZA ZA200810165A patent/ZA200810165B/xx unknown
- 2008-12-31 IL IL196302A patent/IL196302A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200810165B (en) | 2009-09-30 |
| KR20090027672A (ko) | 2009-03-17 |
| IL196302A0 (en) | 2009-09-22 |
| NZ573325A (en) | 2011-05-27 |
| AU2007271469A1 (en) | 2008-01-10 |
| US20080255086A1 (en) | 2008-10-16 |
| MX2008016494A (es) | 2009-01-21 |
| EP2041124B1 (en) | 2013-06-26 |
| AU2007271469B2 (en) | 2012-05-31 |
| WO2008003452A1 (en) | 2008-01-10 |
| US7820707B2 (en) | 2010-10-26 |
| JP2009541404A (ja) | 2009-11-26 |
| CN101484448A (zh) | 2009-07-15 |
| TW200817385A (en) | 2008-04-16 |
| CA2655680A1 (en) | 2008-01-10 |
| EP2041124A1 (en) | 2009-04-01 |
| PE20080378A1 (es) | 2008-04-25 |
| CN101484448B (zh) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR055212A1 (es) | Compuestos heterociclicos como bloqueantes del canal ionico p2x7 | |
| ECSP099177A (es) | Derivados de quinazolinona e isoquinolinona | |
| AR047992A1 (es) | Diaminopirimidinas como antagonistas de p2x3 y p2x2/3 | |
| CR9587A (es) | Derivados de piridazina | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| AR044514A1 (es) | Acidos carboxilicos alfa sustituidos como moduladores ppar | |
| UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| UY31730A (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica. | |
| GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
| ECSP066504A (es) | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina | |
| AR035858A1 (es) | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 | |
| AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
| AR044006A1 (es) | Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| PE20220386A1 (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| ES2532084T3 (es) | Composiciones de topiramato y métodos para su uso | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| CR9703A (es) | Derivados de pirazolona | |
| MX2015014336A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| AR059018A1 (es) | Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k | |
| ECSP10010247A (es) | Derivados heterocíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |